The World Cup kicked off this week and so did our clients, with new appointments, important clinical trial updates and major collaborations announced! The Optimum team was proud to support and attend Weatherden’s Symposium on Women’s Health yesterday, which featured a stellar line-up of speakers to explore how smarter clinical development and regulatory strategy can […]
Posters highlight POLB 001’s potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication · First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations · Second poster demonstrates the potential for POLB […]
Major operational milestone achieved with interim data on track for summer 2026 11 June 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred. This follows the successful completion of […]
Despite the short Bank Holiday week, it’s as busy as ever. Collaborative expansion is in full swing as Bonito Biosciences and DaltonTx join forces, and ViCentra triples Kaleido consumables production capacity through Phillips Medisize partnership. Hansa Biopharma, Poolbeg Pharma and Synklino have been enjoying progress this week, as Hansa reports positive efficacy and safety results […]
FDA feedback supports Poolbeg’s proposed development pathway for POLB 001, providing further clarity for ongoing partnering discussions 26 May 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug […]
